clinical trial · NCT06364072
Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients
PainCT001
brief summary
The proposed study aims to investigate the safety, tolerability, analgesic efficacy, and feasibility of intranasal sufentanil/ketamine (CT001) in pediatric participants attending an acute care (i.e. emergency) setting. The study is a part of the clinical development plan for the development of CT001 nasal spray for treatment of acute pain in children.
started
May 27, 2024
primary completion
May 9, 2025
completion
May 9, 2025
last updated
Feb 2, 2026
official title
Open-label, Prospective Study to Assess the Safety, Tolerability, Analgesic Effect and Feasibility of Intranasal Sufentanil/Ketamine in Pediatric Patients With Moderate or Severe Pain, in an Acute Care Setting
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol